RxDoctor Payments Data

Dean Mast

Emergency Medicine · Olean, NYNPI 1760525406

Payments from drug & device makers

$1,108in general payments, 2019–2025

Across 59 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$414
  • GSK$244
  • Exact Sciences$203
  • AstraZeneca$76
  • Lilly USA, LLC$75
  • AbbVie$34
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$1,108100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,108 in reported general payments places this provider in the 95th percentile of 4,167 emergency medicine providers in New York.

See all emergency medicine providers in New York

Medicare billing

Part B allowed, 2024
$17,257
Medicare patients
53
Services billed
365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$44,037
XareltoRivaroxaban45$37,335
EliquisApixaban29$30,111
JardianceEmpagliflozin28$26,907
TrulicityDulaglutide22$22,814
FarxigaDapagliflozin Propanediol17$21,596
JanuviaSitagliptin Phosphate15$14,090
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen134$4,150
VascepaIcosapent Ethyl11$4,096
Xtampza ErOxycodone Myristate12$4,038
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,299
Albuterol Sulfate HfaAlbuterol Sulfate68$2,541
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,180
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen46$1,717
Omeprazole130$1,508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$414$44,03733 claims
PfizerEliquis$31$30,11129 claims
Lilly USA, LLCTrulicity$75$22,81422 claims
AstraZenecaFarxiga$76$21,59617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,167 emergency medicine providers in New York.

Other emergency medicine in Olean

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →